Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;61(6):911-6.
doi: 10.1007/s00262-011-1158-4. Epub 2011 Nov 25.

Regulatory T cells increase in breast cancer and in stage IV breast cancer

Zhi-kuan Wang  1 , Bo Yang, Hui Liu, Yi Hu, Jun-lan Yang, Liang-liang Wu, Zhen-hong Zhou, Shun-chang Jiao
Affiliations

Regulatory T cells increase in breast cancer and in stage IV breast cancer

Zhi-kuan Wang et al. Cancer Immunol Immunother. 2012 Jun.

Abstract

Expression levels of VEGF and Her-2, levels of T-regulatory (Treg) cells, levels of CD3+ cells, and ratios of Th (CD4+ T cells)/Tr (Treg) cells were compared between stage I, II, III, and IV breast cancer patients (n = 120) prior to chemotherapy and healthy women (n = 30). Cells from peripheral blood were counted by flow cytometry, Her-2 and VEGF expression was detected by pathological examination, and Her-2 was detected by FISH. Breast cancer patients had more Treg cells and a lower ratio of Th/Tr cells than the healthy women. Stage IV breast cancer patients had more Treg cells and a lower ratio of Th/Tr cells than stage I, II, or III breast cancer patients. Patients positive for VEGF had a lower ratio of Th/Tr cells compared with patients negative for VEGF, and those positive for both VEGF and Her-2 also had a lower ratio of Th/Tr cells compared with patients not positive for both VEGF and Her-2. The decreased Th/Tr cells ratio indicates impaired immune function, suggesting that the stage IV breast cancer and the Her-2/VEGF-positive breast cancer patients have lower immune function.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The percentages of CD3+, Treg, and Th cells (a) and the ratios of CD4+/CD8+ cells and Th/Tr cells (b) were compared among healthy adult women (n = 30), breast cancer patients of stage I–III (n = 65), and breast cancer patients at stage IV (n = 55). Data are expressed as means with the standard deviations indicated by the bar. For comparisons where P < 0.05, the * represents a significant difference between stage I–III and the healthy women, the † represents a significant difference between stage IV and the healthy women, and ‡ represents a significant difference between stage I–III and stage IV
Fig. 2
Fig. 2
The immunohistochemistry results evaluated the overexpression of VEGF and Her-2. To evaluate the expression of VEGF, breast tissue sections from healthy women (a) and cancer patients (b) were immunostained with anti-VEGF antibody and visualized by DAB. The detection of Her-2 gene expression status was evaluated by FISH. The results from a normal Her-2 expressing (c) or overexpressing (d) tissue were shown. The scale bar = 50 μm in (a) and (b). The scale bar = 2 μm in (c) and (d)
See this image and copyright information in PMC

References

    1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–360. doi: 10.1146/annurev.immunol.22.012703.104803. - DOI - PubMed
    1. Croci DO, Zacarías Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother. 2007;56(11):1687–1700. doi: 10.1007/s00262-007-0343-y. - DOI - PMC - PubMed
    1. Krupnick AS, Kreisel D, Szeto WY, Popma SH, Amin KM, Moore JS, Rosengard BR. Multiparameter flow cytometric approach for simultaneous evaluation of T lymphocyte endothelial cell interactions. Cytometry. 2001;46(5):271–280. doi: 10.1002/cyto.1168. - DOI - PubMed
    1. Abo-Elenein A, Elgohary S, Hashish A, El-Halaby E. Significance of immunoregulatory T cells in different stages of breast cancer patients. Egyptian J Immunol/Egyptian Ass Immunologists. 2008;15(2):145. - PubMed
    1. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001;194(6):823–832. doi: 10.1084/jem.194.6.823. - DOI - PMC - PubMed

Publication types

Substances